[1]李欣,石三军,周敏,等.酪氨酸激酶抑制剂达沙替尼抗黑色素瘤的体外研究[J].第三军医大学学报,2016,38(23):2479-2485.
 Li Xin,Shi Sanjun,Zhou Min,et al.Effect of tyrosine kinase inhibitor dasatinib on melanoma cells[J].J Third Mil Med Univ,2016,38(23):2479-2485.
点击复制

酪氨酸激酶抑制剂达沙替尼抗黑色素瘤的体外研究(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
38卷
期数:
2016年第23期
页码:
2479-2485
栏目:
基础医学
出版日期:
2016-12-15

文章信息/Info

Title:
Effect of tyrosine kinase inhibitor dasatinib on melanoma cells
作者:
李欣石三军周敏卢来春
第三军医大学药学院教学实验中心, 第三军医大学大坪医院野战外科研究所药剂科
Author(s):
Li Xin Shi Sanjun Zhou Min Lu Laichun

Teaching Experimental Center, College of Pharmacy, Third Military Medical University, Chongqing, 400038; Department of Pharmacy, Institute of Surgery Research, Daping Hospital, Third Military Medical University, Chongqing, 400042, China

关键词:
达沙替尼黑色素瘤细胞增殖细胞迁移细胞凋亡
Keywords:
dasatinib melanoma cell proliferation cell migration apoptosis
分类号:
R739.5; R969; R977.3
文献标志码:
A
摘要:

目的      探讨达沙替尼对小鼠黑色素瘤B16F10细胞株体外增殖、迁移和凋亡的影响。  方法       采用MTT法检测不同浓度(3.125、6.250、12.500、25.000、50.000 μg/mL)达沙替尼在24、48 h对B16F10细胞增殖能力的影响;采用细胞划痕实验和Transwell体外迁移实验检测达沙替尼对B16F10细胞迁移能力的影响;DAPI染色法观察给药后细胞核形态的变化;流式细胞仪检测达沙替尼对B16F10细胞凋亡率和细胞周期的影响;荧光显微镜观察达沙替尼对B16F10细胞线粒体膜电位的影响,并用荧光分光光度计检测Caspase 3和Caspase 9的活化程度。 结果      达沙替尼对B16F10细胞的增殖有抑制作用,并呈浓度和时间依赖性。细胞划痕实验及Transwell体外迁移实验结果表明:达沙替尼能够有效地抑制B16F10细胞的迁移。分别以低、中、高3个浓度(6.250、12.500、25.000 μg/mL)的达沙替尼作用于B16F10细胞24 h后,细胞形态发生明显改变,核裂解,形成多个凋亡小体,凋亡率分别为(34.06±0.83)%、(50.24±1.66)%和(88.91±0.96)%,与对照组比较差异均有统计学意义(P<0.05)。达沙替尼对B16F10细胞周期的影响较小,其中对G1期有微弱的阻滞作用。中浓度(12.500 μg/mL)达沙替尼组能够引起B16F10细胞线粒体膜电位的降低,Caspase 3和Caspase 9活性的增加,表明达沙替尼可能是通过线粒体介导的Caspase通路引起细胞凋亡。 结论      达沙替尼能有效地抑制小鼠黑色素瘤B16F10细胞株体外增殖与迁移,诱导细胞凋亡,有望成为一种有效的抗黑色素瘤药物。

Abstract:

Objective      To determine the effect of dasatinib on the proliferation, migration and apoptosis of murine melanoma cell line B16F10.  Methods      MTT assay was used to detect the proliferation of B16F10 cells after the treatment of dasatinib at different doses (3.125, 6.250, 12.500, 25.000 and 50.000  μg/mL) for different time periods (24 and 48 h). Wound healing assay and Transwell chamber assay were used to assess the effect of dasatinib treatment on the migration of B16F10 cells. DAPI staining was used to observe the cell morphology before and after the treatment. Flow cytometry was employed to analyze the effect of dasatinib on the apoptotic rate and cell cycle of B16F10 cells. Fluorescence microscopy was performed to measure the effects of dasatinib on the mitochondrial membrane potential of B16F10 cells. Fluorescence spectrophotometery was used to measure the activities of Caspase 3 and Caspase 9.  Results     Dasatinib markedly inhibited the proliferation of B16F10 cells in a dose- and time-dependent manner. Wound healing assay and Transwell chamber assay showed that dasatinib effectively suppressed the migration of B16F10 cells. After the cells were treated by 6.250, 12.500 and 25.000  μg/mL dasatinib for 24 h, obvious morphological changes including nuclear fragments and apoptotic bodies were observed, and the apoptotic rate were (34.06±0.83)%, (50.24±1.66)% and (88.91±0.96)%, respectively, which were significant different with that of the control group (P<0.05). Dasatinib had little effect on cell cycle and showed mild arrest on the cells in G1 phase. Dasatinib of 12.500  μg/mL resulted in the reduce of mitochondrial membrane potential and enhanced activities of Caspase 3 and Caspase 9, which indicating that dasatinib may induce cell apoptosis through mitochondria mediated Caspase signal pathway.  Conclusion     Dasatinib effectively inhibits the proliferation and migration, induces the apoptosis in murine melanoma B16F10 cells. It might be used as an effectively therapeutic agent against human melanoma.
 

参考文献/References:

[1]Mazurenko N N,  Tsyganova I V,  Lushnikova A A,  et al. The spectrum of oncogene mutations differs among melanoma subtypes[J]. Molecular Biology,  2015,  49(6):  917-923. DOI:  10.1134/S0026893315060163
[2]Mccormack P L,  Keam S J. Dasatinib:  a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia [J]. Drugs,  2011,  71(13):  1771-1795. DOI:  10.2165/11207580-000000000-00000
[3]Araujo J,  Logothetis C. Dasatinib:  a potent SRC inhibitor in clinical development for the treatment of solid tumors[J]. Cancer Treat Rev, 2010, 36(6): 492-500. DOI:  10.1016/j.ctrv.2010.02.015
[4]Das G C,  Holiday D,  Gallardo R,  et al. Taxol-induced cell cycle arrest and apoptosis:  doseresponse relationship in lung cancer cells of different wild-type p53 status and under isogenic condition[J]. Cancer Lett, 2001, 165(2): 147-153. DOI:  10.1016/S0304-3835(01)00404-9
[5]Arora A,  Scholar E M. Role of Tyrosine Kinase Inhibitors in Cancer Therapy[J]. J Pharmacol Exp Ther, 2005, 315(3): 971-979. DOI : 10.1124/jpet.105.084145
[6]Tokuhisa Y,  Lidsky M E,  Toshimitsu H,  et al. SRC family kinase inhibition as a novel strategy to augment melphalanbased regional chemotherapy of advanced extremity melanoma [J]. Ann Surg Oncol, 2014, 21(3): 1024-1030. DOI:  10.1245/s10434-013-3387-6
[7]Sullivan R J,  Flaherty K. MAP kinase signaling and inhibition in melanoma[J]. Oncogene,  2013,  32(19):  2373-2379. DOI:  10.1038/onc.2012.345
[8]Dalgic C T,  Kaymaz B T,  ozkan M C,  et al. Investigating the Role of JAK/STAT Pathway on Dasatinib-Induced Apoptosis for CML Cell Model K562[J]. Clin Lymphoma Myeloma Leuk,  2015,  15(Suppl):  S161-S166. DOI:  10.1016/j.clml.2015.02.012
[9]Wang Z,  Li L,  Shao Z,  et al. The combination of dasatinib and gefitinib enhances the killing effect of gefitinib on HCC827 lung cancer cells[J]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 2016, 32(5): 595-599.
[10]Kim E M H,  Mueller K,  Gartner E,  et al. Dasatinib is synergistic with cetuximab and cisplatin in triplenegative breast cancer cells[J]. J Surg Res,  2013,  185(1):  231-239. DOI:  10.1016/j.jss.2013.06.041
[11]Niles L P,  Armstrong K J,  Rincón Castro L M,  et al. Neural stem cells express melatonin receptors and neurotrophic factors:  colocalization of the MT1 receptor with neuronal and glial markers[J]. BMC Neurosci,  2004,  5:  41. DOI:  10.1186/1471-2202-5-41
[12]Dong Y,  Liang C,  Zhang B,  et al. Bortezomib enhances the therapeutic efficacy of dasatinib by promoting cKIT internalizationinduced apoptosis in gastrointestinal stromal tumor cells[J]. Cancer Lett,  2015,  361(1):  137-146. DOI:  10.1016/j.canlet.2015.02.044
[13]Buettner R,  Mesa T,  Vultur A,  et al. Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells[J]. Mol Cancer Res,  2008,  6(11):  1766-1774. DOI:  10.1158/15417786.MCR-08-0169 

相似文献/References:

[1]李毅,肖顺武,张学军,等.颅内原发性黑色素瘤诊治体会[J].第三军医大学学报,2008,30(06):551.
[2]王琳,吴文慧,杨春江,等.颌面部恶性黑色素瘤的病理分析[J].第三军医大学学报,2005,27(02):135.
[3]陈恒君,李惠,陈瑾,等.人Dickkopf1基因腺病毒载体的构建及感染黑色素瘤后β-catenin表达的研究[J].第三军医大学学报,2010,32(12):1286.
 Chen Hengjun,Li Hui,Chen Jin,et al.Construction of Dickkopf1-expressing recombinant adenovirus and its effect on β-catenin expression in A375 cells[J].J Third Mil Med Univ,2010,32(23):1286.
[4]李芙蓉,王跃.双歧杆菌脂磷壁酸对B16荷瘤小鼠Fas/FasL表达的影响[J].第三军医大学学报,2010,32(12):1308.
 Li Furong,Wang Yue.Effects of lipoteichoic acid of bifidobacterium on Fas/FasL expression in B16 tumor-bearing mice[J].J Third Mil Med Univ,2010,32(23):1308.
[5]李育平,张恒柱,佘磊,等.原发性胸椎管内恶性黑色素瘤误诊为脊膜瘤1例[J].第三军医大学学报,2013,35(11):1176.
[6]董留建,王树凯.颅内14例恶性黑色素瘤的临床诊断及治疗体会[J].第三军医大学学报,2011,33(07):756.
[7]谢珊珊,程敬亮,张勇.筛窦原发性黑色素瘤1例[J].第三军医大学学报,2014,36(07):673.
[8]石统东,王莉,贾正才,等.MART-1特异性治疗性多肽诱导CD8~+T细胞应答的研究[J].第三军医大学学报,2003,25(10):0.[doi:10.16016/j.1000-5404.2003.10.011 ]
 SHI Tong dong,WANG Li,JIA Zheng cai,et al.[J].J Third Mil Med Univ,2003,25(23):0.[doi:10.16016/j.1000-5404.2003.10.011 ]
[9]刘触灵.纵隔转移性黑色素瘤1例[J].第三军医大学学报,2003,25(18):0.[doi:10.16016/j.1000-5404.2003.18.009 ]
[10]梁智勇,史景泉,魏泓,等.应用AFLP法检测小鼠黑色素瘤B16基因组的变异[J].第三军医大学学报,2001,23(06):0.[doi:10.16016/j.1000-5404.2001.06.016 ]
 LIANG Zhi yong,SHI Jing quan,WEI Hong,et al.[J].J Third Mil Med Univ,2001,23(23):0.[doi:10.16016/j.1000-5404.2001.06.016 ]

更新日期/Last Update: 2016-12-05